Overview
Lobbying Costs
1,000,000€ - 1,249,999€
Financial year: Jan 2023 - Dec 2023
Lobbyists (Full time equivalent)
2.4 Fte (8)
Lobbyists with EP accreditation
4
High-level Commission meetings
6
Lobbying Costs over the years
-
Info
AbbVie (ABBV)
EU Transparency Register
934069612666-51 First registered on 20 Jan 2014
Goals / Remit
AbbVie is a Specialty-focused, research-based biopharmaceutical company focused on developing new products and new ways to help people manage some of the most serious health conditions. We are scientists, researchers, communicators, manufacturing specialists, and regulatory experts.
AbbVie began as the pharmaceutical leader, Abbott, which was founded in 1888 by Chicago physician, Dr. Wallace Abbott. Since then, Abbott has evolved to become a global healthcare leader, delivering innovative pharmaceutical, nutritional, diagnostic, and medical products to people in more than 150 countries.
On January 1, 2013, AbbVie was founded, a global biopharmaceutical company with the focus and capabilities to address some of the world's greatest health challenges. AbbVie has the stability, resources, expertise, and passion to discover, develop, and bring to market groundbreaking science to solve the biggest health problems that face the world today (...)Main EU files targeted
- Pharmaceutical Strategy, and in particular review of the basic pharmaceutical legislation, of the Orphan Medicinal Products Regulation, and of the Paediatric Medicines Regulation
- European Health Data Space
- Industrial Policies and IP Action Plan, and in particular questions around patents, SPC and so on.
- Joint Procurement for medical countermeasures
- Competition in the pharmaceutical sector
- Revision of Medical Device and IVD Regulation
- Urban Waste water Directive
- Packaging and Packaging waste
- European Commission activities around ensuring effective, resilient and sustainable healthcare systems
- Access to Medicines
- Beating cancer planAddress
Head Office
North Waukegan Road, 1
North Chicago IL 60064
UNITED STATESEU Office
Square de Meeus 37
Brussels 1000
BELGIUMWebsite
-
People
Total lobbyists declared
8
Employment time Lobbyists 75% 2 25% 2 10% 4 Lobbyists (Full time equivalent)
2.4
Lobbyists with EP accreditation
All Lobbyists with EP accreditation over time
4 accreditations were / are live (in bold) for the selected state of 21 Nov 2024
Name Start date End Date Janusz LINKOWSKI 30 Sep 2024 30 Sep 2025 Paul Nagels 30 Sep 2024 30 Sep 2025 Aurélie Derinck 01 Oct 2024 30 May 2025 Philip SCHWAB 30 Sep 2024 30 Sep 2025 Philip SCHWAB 07 Jun 2023 07 Jun 2024 Christian BARACAT 22 Sep 2023 21 Sep 2024 Janusz LINKOWSKI 20 Mar 2024 04 Oct 2024 Felix KUBITSCHEK 22 Sep 2023 01 Feb 2024 Felix KUBITSCHEK 12 Jul 2022 12 Jul 2023 Christian BARACAT 25 Jun 2022 24 Jun 2023 Ms Jennifer SHUM 05 Feb 2016 02 Feb 2017 Complementary Information
None declared
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
- American Chamber of Commerce to the EU
- European Federation of Pharmaceutical Industries and Association (EFPIA)
- EuropaBio – the European Association of Bio-Industries
- Friends of EuropeMember organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2023 - Dec 2023
Lobbying costs for closed financial year
1,000,000€ - 1,249,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount rpp group 100,000€ - 199,999€ fipra, support for the achieve coalition 50,000€ - 99,999€ grayling 25,000€ - 49,999€ Intermediaries for current year
Name rpp group fti consulting Closed year Costs
1,000,000€ - 1,249,999€
Other financial info
Since 2022 and the new interinstitutonal agreement and the guidelines issued in that context, the reporting structure has changed. This led to adding additional employees and their salaries whose activities are now considered in-scope, as well as to counting the membership fees to organization we are members of (which we previously excluded to avoid double reporting).
-
EU Structures
Groups (European Commission)
None declared
Groups (European Parliament)
N/A
Communication activities
AbbVie has supported a number of roundtables that were hosted by members of the European Parliament and politicla parties, and has also participated in the EU public debate through op-eds that were published in the relevant trade press.
Other activities
None declared
Meetings
Meetings
6 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.
-
Date 21 Sep 2023 Location Ireland Subject Discussions covered AbbVie’s presence in Europe including 5 major sites in Ireland; the sector’s demand for skills and training; the pharmaceutical strategy for Europe and access to medicine in Ireland. Cabinet Cabinet of Commissioner Mairead Mcguinness Portfolio Financial services, financial stability and Capital Markets Union Attending - Patricia Reilly (Cabinet member)
- Mairead McGuinness (Commissioner)
-
Date 05 Jun 2023 Location Brussels Subject Trade & Technology Council, Global Steel and Aluminum Arrangement, Critical Minerals Agreement Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis Portfolio An Economy that Works for People Attending - Zaneta Vegnere (Cabinet member)
- Elina Melngaile (Cabinet member)
Other Lobbyists -
Date 24 Nov 2020 Location Brussels (online) Subject Pharmaceutical innovation and research in Europe Cabinet Cabinet of Executive Vice-President Margrethe Vestager Portfolio Europe Fit for Digital Age Attending - Alina-Stefania Ujupan (Cabinet member)
-
Date 24 May 2018 Location Brussels Subject Business discussion Cabinet Cabinet of Commissioner Phil Hogan Portfolio Agriculture & Rural Development Attending - Tom Tynan (Cabinet member)
-
Date 27 Mar 2018 Location Brussels Subject IP regime generic manufacturers in the pharmaceutical industry Cabinet Cabinet of Commissioner Pierre Moscovici Portfolio Economic and Financial Affairs, Taxation and Customs Attending - Leila Fernandez-Stembridge (Cabinet member)
-
Date 26 Mar 2018 Location Brussels Subject SPC waiver Cabinet Cabinet of Vice-President Cecilia Malmström Portfolio Trade Attending - Nele Eichhorn (Cabinet member)
Other Lobbyists